[1] Baghi M,Mack MG,Hambek M,at al.Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.Head Neck,2007,29(2):104-108.
[2] Muldcr WJ,van der Schaft DW,Hantvast PA,et al.Early in vivo assessment of angiostatic therapy efficacy by molecular MRI.FASEB J,2007,21(2):378-383.
[3] Khankan AA,Murakami T,Onishi H,et al.Hepatocellular carcinoma treated with radio frequency ablation:an early evaluation with magnetic resonance imaging.J Magn Reson Imaging,2008,27(3):546-551.
[4] Hayashida Y,Yakushiji T,Awai K,et al.Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image:Initial results.Eur Radiol,2006,16(12):2637-2643.
[5] Schepkin VD,Lee KC,Kuszpit K,et al.Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.NMR Biomed,2006,19(8):1035-1042.
[6] Dyke JP,Sanelli PC,Voss HU,et al.Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastema multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.J Neurooncol,2007,82(1):103-110.
[7] Oriol A,Valverde D,Capellades J,et al.In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrow.MAGMA,2007,20(2):93-101.
[8] Kumar M,Jagannathan NR,Seenu V,et al.Monitoring the therapeutic response of locally advanced breast cancer patients:sequential in vivo proton MR spectroscopy study.J Magn Reson Imaging,2006,24(2):325-332.
[9] Wile GE,Leyendecker JR,Krehbiel KA,et al.CT and MR imaging after imaging-guided thermal ablation of renal neoplasms.Radiographics,2007,27(2):325-339.
[10] Makari Y,Yasuda T,Doki Y,et al.Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers.J Surg Oncol,2007,96(3):220-229.
[11] Si Q,Mu H,Yan G,et al.Individualized treatment models based on blood supply characteristics in hepatocellular carcinoma using color Doppler bemodynamics.Hepatagastroenterology,2007,54(74):334-341.
[12] Si Q,Mu H,Yan G,et al.Individualized treatment models based on blood supply characteristics in hepatocellular carcinoma using color Doppler bemodynamics.Hepatagastroenterology,2007,54(74):334-341.
[13] Lamuraglia M,Lassau N,Garbay JR,et al.Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences:a prospective phase II study.EurJ Radiol,2005,56(3):376-381.
[14] Nabmias C,Hanna WT,Wahl LM,et al.Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.J Nucl Med,2007,48(5):744-751.
[15] Berard V,Rousseau JA,Cadorette J,et al.Dynamic imaging of transient metabolic processes by small-animal PET for the evaluation of photosensitizers in photodynamic therapy of cancer.J Nucl Med,2006,47(7):1119-1126.
[16] Pottgen C,Levegrtin S,Theegarten D,et al.Value of 18F-fluoro-2-deoxy-D-glucose-pesitren emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after necadjuvant chemoradiotherapy.Clin Cancer Res,2006,12(1):97-106.
[17] Wieder HA,Beer A J,Lordick F,et al.Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.J Nucl Med,2005,46(12):2029-2034.
[18] Rousseau C,Devillers A,Sagan C,et al.Monitoring of early response to neoadjuvant chemotherapy in stage Ⅱ and Ⅲ breast cancer by[18F]fluorodeoxyglucose positron emission tomography.J Clin Oncel,2006,24(34):5366-5372.
[19] Goshen E,Davidsen T,Zwas ST,et al.PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.Tecbol Cancer Res Treat,2006,5(1):37-43.
[20] Bleichner-Perez S,Le Jeune F,Duhais F,et al.99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent,primary brain tumors.Nucl Med Commun,2007,28(12):888-894.
[21] Akgun A,Cok G,Karapolat I,et al.99mTc-MIBI SPECT in prediction of prognosis in patients with small cell lung cancer.Ann Nucl Med,2006,20(4):269-275.